Nabil Daoud – President & General Manager, Spain-Portugal-Greece, Lilly

Lilly’s Nabil Daoud highlights the evolution in the firm’s Spanish manufacturing and R&D footprint in recent years, discussed launch plans for its next-generation diabetes and obesity treatments, and outlines some of the key trends currently impacting healthcare in Spain.  
Four years ago, a molecule discovered and designed by scientists in Alcobendas for the treatment of metastatic breast cancer was approved by regulatory agencies across the world. Lilly wants to repeat history and discover another medicine that makes the transition to becoming a commercially available drug
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report